International Diabetes Federation: IDF Diabetes Atlas, 7th edition. Brussels: International Diabetes Federation, 2015.
2.
Food and Agriculture Organization of the United Nations, Statistics Division. Food Balance. 2015. http://faostat3.fao.org/browse/FB/*/E (accessed January19, 2016).
3.
NgM, FreemanM, FlemingT, et al.: Smoking prevalence and cigarette consumption in 187 countries, 1980–2012. JAMA, 2014; 311:183–192.
4.
PerkJ, De BackerG, GohlkeH, et al.: European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J, 2012; 33:1635–1701.
5.
Healthcare Insurance Fund of Republic of Macedonia: Annual Report for 2014. www.fzo.org.mk/default.asp?ItemID=E47E1E538B68294BB0A1077B2DAFA4D9 (accessed January19, 2016).
6.
Ministry of Health of Republic of Macedonia: Program for providing insulin, glucagon, insulin needles, test strips for glycaemia, and education for treatment and control of diabetes [in Macedonian]. Official J Republic Macedonia, 2014; 196:78–80.
7.
Law for Amendments of Law on Healthcare [in Macedonian]. Official J Republic Macedonia, 2015; 10:41–42.
8.
Healthcare guidelines on treatment and control of type 2 diabetes [in Macedonian]. Official J Republic Macedonia, 2015; 40:15–34.
9.
National Institute for Health and Care Excellence: Continuous Subcutaneous Insulin Infusion for the Treatment of Diabetes Mellitus. Technology Appraisal Guidance. https://www.nice.org.uk/guidance/ta151 (accessed January19, 2016).
10.
AronsonR, CohenO, CongetI, et al.: OpT2mise: a randomized controlled trial to compare insulin pump therapy with multiple daily injections in the treatment of type 2 diabetes—research design and methods. Diabetes Technol Ther, 2014; 16:414–420.
11.
ReznikY, CohenO, AronsonR, et al.: Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet, 2014; 384:1265–1272.
12.
ReznikY, HuangS; OpT2mise Study Group: Reductions in A1C with pump therapy in type 2 diabetes are independent of C-peptide and anti-glutamic acid decarboxylase antibody concentrations. Diabetes Technol Ther, 2014; 16:816–818.
13.
CongetI, CastanedaJ, PetrovskiG, et al.: The impact of insulin pump therapy on glycemic profiles in patients with type 2 diabetes: data from the OpT2mise Study. Diabetes Technol Ther, 2016; 18:22–28.
